TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

EXTENSION OF LONG STOP DATE IN RELATION TO THE ISSUE OF H SHARES UNDER GENERAL MANDATE

Reference is made to the Company's announcement dated July 21, 2026 (the "**Announcement**") regarding the license and collaboration with Qilu and the proposed issuance of 63,222,744 H Shares to the Subscriber. Unless otherwise defined, capitalized terms in this announcement shall have the same meaning as defined in the Announcement.

As disclosed in the Announcement, the completion of the Subscription shall take place after satisfaction or waiver of the conditions precedent under the Subscription Agreement. In the event that the conditions of the Subscription are not fulfilled or waived by the Long Stop Date (being August 20, 2026 or such other date as may be agreed between the parties to the Subscription Agreement), the Subscription Agreement will be terminated.

As additional time is required for the parties to the Subscription Agreement to satisfy certain conditions for the issuance of the Subscription Shares, on August 20, 2026, the parties to the Subscription Agreement have agreed to extend the Long Stop Date from August 20, 2026 to September 20, 2026.

Save and except for the aforesaid extension of the Long Stop Date, all other terms and conditions of the Subscription Agreement, the License and Collaboration Agreement and the Supplies and Commercialization Agreement as detailed in the Announcement remain unchanged and continue to remain in full force and effect.

As Completion of the Subscription is subject to satisfaction (or waiver) of a number of conditions under the Subscription Agreement, the Subscription may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 20, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.